<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618616</url>
  </required_header>
  <id_info>
    <org_study_id>ZPL389/102</org_study_id>
    <nct_id>NCT02618616</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of Once Daily Oral ZPL-3893787- 18 (30 mg) Administered for 12 Weeks in Adult Subjects With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziarco Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziarco Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a randomized, double blind, placebo controlled, parallel group study in 129 subjects&#xD;
      with moderate to severe psoriasis with a PASI score of at least 10. Following run-in,&#xD;
      subjects were randomized and received either oral 30 mg ZPL-3893787 once daily or placebo&#xD;
      once daily for 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, double blind, placebo controlled, parallel group study in 129 subjects&#xD;
      with moderate to severe psoriasis with a Psoriasis Area and Severity Index (PASI) score of at&#xD;
      least 10 and an Investigator's Global Assessment (IGA) of 3 (0-4 scale). Following run-in&#xD;
      subjects received either oral 30 mg ZPL-3893787 once daily or placebo once daily for 12&#xD;
      weeks. Subjects attended the clinic at Baseline (Day 0) when they were reviewed and confirmed&#xD;
      they met inclusion/exclusion criteria. Subjects were then randomized and received either oral&#xD;
      30 mg ZPL-3893787 once daily or placebo once daily for 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2016</start_date>
  <completion_date type="Actual">December 22, 2016</completion_date>
  <primary_completion_date type="Actual">December 22, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Psoriasis Assessment of Severity Index (PASI) at Week 12</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>The PASI is an assessment routinely used for evaluating and grading the severity of psoriatic lesions and their response to therapy. PASI divides the body into 4 regions: the head, trunk, upper extremities (arms) and lower extremities (legs). Each of these areas is assessed separately for erythema, in duration and scaling; these symptoms are scored on a 5-point scale from 0-4, where 0 = no symptoms and 4 =very marked. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents a reduction of at least 75% from baseline in the PASI score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PASI-50 and PASI-75 Responders at Week 12</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>PASI-75 and PASI-50 are defined as a 75% and 50% reduction, respectively, from baseline in PASI score at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Investigator Global Assessment (IGA) at Week 12</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>An overall assessment of the severity of psoriasis was made, by the investigator, using the IGA at each visit. IGA scores take values on a 5-point scale from 0-4, where 0 = clear to 4 = severe disease. Responder is defined as a score of clear or almost clear, or a reduction of ≥2 levels. Success is defined as a score of clear or almost clear. Subjects with discontinued and missing data categories at Week 12 were considered non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Numerical Rating Scale (NRS) for Pruritus (Worst Itch) at Week 12</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>The pruritus NRS is an assessment tool used to assess the subject's worst itch as a result of psoriasis in the last 12 hours. The subjects completed the NRS each morning on (or soon after) rising and evening prior to retiring to bed. The subjects completed the NRS each morning on (or soon after) rising and evening prior to retiring to bed. They were asked the following question: On a scale of 0 (no itching) to 10 (itching as bad as you can imagine), please rate the worst itching that you felt over the last 12 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) a Week 12</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>At the end of treatment (Week 12) or early termination visit, the subject was asked to rate their degree of improvement (or worsening) of their psoriasis compared to before the start of treatment with study drug, using a 7-point scale, standardized PGIC.&#xD;
Since the start of the study (dosing), my overall status is:&#xD;
Very much improved&#xD;
Much improved&#xD;
Minimally improved&#xD;
No change&#xD;
Minimally worse&#xD;
Much worse&#xD;
Very much worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Surface Area (BSA) and Percentage Change From Baseline at Week 12</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Assessment of the percentage of a subject's BSA affected by psoriasis was made by best estimates of the investigator at each visit. Hand-size measurement was considered to be the &quot;best estimate&quot; to measure the BSA by the investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Daytime and Night Time NRS for Pruritus (Worst Itch) at Week 12</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>The subjects completed the NRS each morning on (or soon after) rising and evening prior to retiring to bed. They were asked the following question: On a scale of 0 (no itching) to 10 (itching as bad as you can imagine), please rate the worst itching that you felt over the last 12 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the NRS for Sleep Disturbance at Week 12</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>In the morning subjects were asked the following question to determine the level of sleep disturbance due to itching: On a scale of 0 (no sleep disturbance) to 10 (awake all night), please rate how much your sleep was disturbed by itch last night.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total, Daytime and Night Time Duration of Itching at Week 12</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Subjects were asked the following question to determine their duration of itching: Over the last 12 hours approximately how many hours, if any, did you itch?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants for Each Verbal Rating Scale (VRS) Score for Pruritus at Week 12</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Subjects were asked to rate their itch over the last 12 hours using a list of adjectives describing different levels of symptom intensity: Over the last 12 hours how would you rate your itch? No itch; Mild; Moderate and Severe; Pruritus was evaluated by the subject, using the eDiary, twice daily for 1 week prior to the start of study treatment (run-in period) and during treatment (baseline to Day 84).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>ZPL-389</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally once daily (OD) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZPL-3893787</intervention_name>
    <arm_group_label>ZPL-389</arm_group_label>
    <other_name>ZPL389</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A documented history of moderate to severe plaque psoriasis for at least 6 months&#xD;
             prior to screening.&#xD;
&#xD;
          -  Male or female, aged ≥18 years.&#xD;
&#xD;
          -  Psoriasis Area and Severity Index (PASI) ≥10 at both Screening and Day 0.&#xD;
&#xD;
          -  An Investigator's Global Assessment (IGA) score ≥ 3 at both Screening and Day 0.&#xD;
&#xD;
          -  Psoriasis affecting ≥10% body surface area (BSA) at Screening and Day 0.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current diagnosis of Pustular, Guttate, Erythrodermic, exfoliative or only nail&#xD;
             psoriasis or a diagnosis of inverse psoriasis without having plaque psoriasis.&#xD;
&#xD;
          -  Concurrent skin disease (e.g. acne) of such severity in the study area that it could&#xD;
             interfere with the study evaluation or presence of skin comorbidities that may&#xD;
             interfere with study assessments.&#xD;
&#xD;
          -  Active skin infections (e.g. impetigo, abscesses) or any other clinically apparent&#xD;
             infections.&#xD;
&#xD;
          -  Biologic treatments for psoriasis (e.g. Enbrel, Humira, Stelara, Cosentyx) within 3&#xD;
             months of the start of the Run-In.&#xD;
&#xD;
          -  Phototherapy (e.g. UVA, UVB, PUVA) within 4 weeks of the start of the Run-In.&#xD;
&#xD;
          -  Oral calcineurin inhibitors and immunosuppressants (e.g. cyclosporine, azathioprine,&#xD;
             methotrexate) within 4 weeks of the start of the Run-In.&#xD;
&#xD;
          -  Systemic corticosteroids within 4 weeks of the start of the Run-In.&#xD;
&#xD;
          -  Oral antihistamines and leukotriene inhibitors and tricyclic antidepressants within 1&#xD;
             week of the start of the Run-In.&#xD;
&#xD;
          -  Topical steroids (any potency), topical calcineurin inhibitors (tacrolimus,&#xD;
             pimecrolimus), salicylic acid and urea containing treatments and coaltar preparations,&#xD;
             topical and oral retinoids and vitamin D derivatives, within 1 week of the start of&#xD;
             the Run-In.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Belgium Study Centre</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belgium Study Centre</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belgium Study Centre</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belgium Study Centre</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belgium Study Centre</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belgium Study Centre</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Study Centre</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Study Centre</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Study Centre</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Study Centre</name>
      <address>
        <city>Hanover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Study Centre</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Study Centre</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polish Study Centre</name>
      <address>
        <city>Bialystok</city>
        <zip>15-430</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polish Study Centre</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-405</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polish Study Centre</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polish Study Centre</name>
      <address>
        <city>Lublin</city>
        <zip>20-552</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polish Study Centre</name>
      <address>
        <city>Poznan</city>
        <zip>60-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polish Study Centre</name>
      <address>
        <city>Tarnow</city>
        <zip>, 33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polish Study Centre</name>
      <address>
        <city>Wrocław</city>
        <zip>50-220</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polish Study Centre</name>
      <address>
        <city>Łódź</city>
        <zip>90-553</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK Study Centre</name>
      <address>
        <city>Blackpool</city>
        <zip>FY2 0JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK Study Centre</name>
      <address>
        <city>Bridgetown</city>
        <zip>WS110BN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK Study Centre</name>
      <address>
        <city>Leeds</city>
        <zip>WS110BN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK Study Centre</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9NQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 27, 2015</study_first_submitted>
  <study_first_submitted_qc>November 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <results_first_submitted>April 20, 2021</results_first_submitted>
  <results_first_submitted_qc>June 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 20, 2021</results_first_posted>
  <disposition_first_submitted>August 25, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>August 25, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 1, 2020</disposition_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Each subject had a screening visit to confirm suitability to enter the study, followed by 7-day run-in period.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ZPL-389</title>
          <description>Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally once daily (OD) for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to comply with dosing/evaluation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn by subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS): All randomized subjects who received at least one dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>ZPL-389</title>
          <description>Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally OD for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="129"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.5" spread="13.82"/>
                    <measurement group_id="B2" value="43.2" spread="12.64"/>
                    <measurement group_id="B3" value="44.1" spread="13.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.24" spread="3.494"/>
                    <measurement group_id="B2" value="27.86" spread="3.575"/>
                    <measurement group_id="B3" value="28.12" spread="3.509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Psoriasis Assessment of Severity Index (PASI) at Week 12</title>
        <description>The PASI is an assessment routinely used for evaluating and grading the severity of psoriatic lesions and their response to therapy. PASI divides the body into 4 regions: the head, trunk, upper extremities (arms) and lower extremities (legs). Each of these areas is assessed separately for erythema, in duration and scaling; these symptoms are scored on a 5-point scale from 0-4, where 0 = no symptoms and 4 =very marked. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents a reduction of at least 75% from baseline in the PASI score.</description>
        <time_frame>From baseline to week 12</time_frame>
        <population>Full analysis set (FAS): All randomized subjects who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>ZPL-389</title>
            <description>Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally OD for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Psoriasis Assessment of Severity Index (PASI) at Week 12</title>
          <description>The PASI is an assessment routinely used for evaluating and grading the severity of psoriatic lesions and their response to therapy. PASI divides the body into 4 regions: the head, trunk, upper extremities (arms) and lower extremities (legs). Each of these areas is assessed separately for erythema, in duration and scaling; these symptoms are scored on a 5-point scale from 0-4, where 0 = no symptoms and 4 =very marked. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents a reduction of at least 75% from baseline in the PASI score.</description>
          <population>Full analysis set (FAS): All randomized subjects who received at least one dose of study treatment.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.043" spread="38.4436"/>
                    <measurement group_id="O2" value="-37.361" spread="32.3581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA of PASI at Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8495</p_value>
            <p_value_desc>The 1-sided p-value tests if the ZPL-389 Least square (LS) mean is &lt; the placebo LS mean.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>least square difference</param_type>
            <param_value>8.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>8.4</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PASI-50 and PASI-75 Responders at Week 12</title>
        <description>PASI-75 and PASI-50 are defined as a 75% and 50% reduction, respectively, from baseline in PASI score at Week 12.</description>
        <time_frame>From baseline to week 12</time_frame>
        <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>ZPL-389</title>
            <description>Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally OD for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PASI-50 and PASI-75 Responders at Week 12</title>
          <description>PASI-75 and PASI-50 are defined as a 75% and 50% reduction, respectively, from baseline in PASI score at Week 12.</description>
          <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PASI-50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI-75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic Regression PASI-50</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9058</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.562</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic Regression PASI-75</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5422</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.946</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>2.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in Investigator Global Assessment (IGA) at Week 12</title>
        <description>An overall assessment of the severity of psoriasis was made, by the investigator, using the IGA at each visit. IGA scores take values on a 5-point scale from 0-4, where 0 = clear to 4 = severe disease. Responder is defined as a score of clear or almost clear, or a reduction of ≥2 levels. Success is defined as a score of clear or almost clear. Subjects with discontinued and missing data categories at Week 12 were considered non-responders.</description>
        <time_frame>From baseline to week 12</time_frame>
        <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>ZPL-389</title>
            <description>Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally OD for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Investigator Global Assessment (IGA) at Week 12</title>
          <description>An overall assessment of the severity of psoriasis was made, by the investigator, using the IGA at each visit. IGA scores take values on a 5-point scale from 0-4, where 0 = clear to 4 = severe disease. Responder is defined as a score of clear or almost clear, or a reduction of ≥2 levels. Success is defined as a score of clear or almost clear. Subjects with discontinued and missing data categories at Week 12 were considered non-responders.</description>
          <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Numerical Rating Scale (NRS) for Pruritus (Worst Itch) at Week 12</title>
        <description>The pruritus NRS is an assessment tool used to assess the subject's worst itch as a result of psoriasis in the last 12 hours. The subjects completed the NRS each morning on (or soon after) rising and evening prior to retiring to bed. The subjects completed the NRS each morning on (or soon after) rising and evening prior to retiring to bed. They were asked the following question: On a scale of 0 (no itching) to 10 (itching as bad as you can imagine), please rate the worst itching that you felt over the last 12 hours.</description>
        <time_frame>From baseline to week 12</time_frame>
        <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>ZPL-389</title>
            <description>Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally OD for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Numerical Rating Scale (NRS) for Pruritus (Worst Itch) at Week 12</title>
          <description>The pruritus NRS is an assessment tool used to assess the subject's worst itch as a result of psoriasis in the last 12 hours. The subjects completed the NRS each morning on (or soon after) rising and evening prior to retiring to bed. The subjects completed the NRS each morning on (or soon after) rising and evening prior to retiring to bed. They were asked the following question: On a scale of 0 (no itching) to 10 (itching as bad as you can imagine), please rate the worst itching that you felt over the last 12 hours.</description>
          <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.40" spread="2.659"/>
                    <measurement group_id="O2" value="-1.78" spread="2.810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Change (PGIC) a Week 12</title>
        <description>At the end of treatment (Week 12) or early termination visit, the subject was asked to rate their degree of improvement (or worsening) of their psoriasis compared to before the start of treatment with study drug, using a 7-point scale, standardized PGIC.&#xD;
Since the start of the study (dosing), my overall status is:&#xD;
Very much improved&#xD;
Much improved&#xD;
Minimally improved&#xD;
No change&#xD;
Minimally worse&#xD;
Much worse&#xD;
Very much worse</description>
        <time_frame>From baseline to week 12</time_frame>
        <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>ZPL-389</title>
            <description>Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally OD for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Change (PGIC) a Week 12</title>
          <description>At the end of treatment (Week 12) or early termination visit, the subject was asked to rate their degree of improvement (or worsening) of their psoriasis compared to before the start of treatment with study drug, using a 7-point scale, standardized PGIC.&#xD;
Since the start of the study (dosing), my overall status is:&#xD;
Very much improved&#xD;
Much improved&#xD;
Minimally improved&#xD;
No change&#xD;
Minimally worse&#xD;
Much worse&#xD;
Very much worse</description>
          <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Surface Area (BSA) and Percentage Change From Baseline at Week 12</title>
        <description>Assessment of the percentage of a subject's BSA affected by psoriasis was made by best estimates of the investigator at each visit. Hand-size measurement was considered to be the &quot;best estimate&quot; to measure the BSA by the investigators.</description>
        <time_frame>From baseline to week 12</time_frame>
        <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>ZPL-389</title>
            <description>Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally OD for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Surface Area (BSA) and Percentage Change From Baseline at Week 12</title>
          <description>Assessment of the percentage of a subject's BSA affected by psoriasis was made by best estimates of the investigator at each visit. Hand-size measurement was considered to be the &quot;best estimate&quot; to measure the BSA by the investigators.</description>
          <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
          <units>percentage of BSA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="10.77"/>
                    <measurement group_id="O2" value="-4.2" spread="9.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Daytime and Night Time NRS for Pruritus (Worst Itch) at Week 12</title>
        <description>The subjects completed the NRS each morning on (or soon after) rising and evening prior to retiring to bed. They were asked the following question: On a scale of 0 (no itching) to 10 (itching as bad as you can imagine), please rate the worst itching that you felt over the last 12 hours.</description>
        <time_frame>From baseline to week 12</time_frame>
        <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>ZPL-389</title>
            <description>Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally once daily (OD) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Daytime and Night Time NRS for Pruritus (Worst Itch) at Week 12</title>
          <description>The subjects completed the NRS each morning on (or soon after) rising and evening prior to retiring to bed. They were asked the following question: On a scale of 0 (no itching) to 10 (itching as bad as you can imagine), please rate the worst itching that you felt over the last 12 hours.</description>
          <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NRS for pruritus (daytime) at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.32" spread="2.251"/>
                    <measurement group_id="O2" value="4.52" spread="2.748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in baseline at Week 12 (daytime)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.40" spread="2.765"/>
                    <measurement group_id="O2" value="-1.42" spread="2.779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NRS for pruritus (night time) at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.19" spread="2.299"/>
                    <measurement group_id="O2" value="4.34" spread="2.682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in baseline at Week 12 (night time)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="2.856"/>
                    <measurement group_id="O2" value="-1.31" spread="2.860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the NRS for Sleep Disturbance at Week 12</title>
        <description>In the morning subjects were asked the following question to determine the level of sleep disturbance due to itching: On a scale of 0 (no sleep disturbance) to 10 (awake all night), please rate how much your sleep was disturbed by itch last night.</description>
        <time_frame>From baseline to week 12</time_frame>
        <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>ZPL-389</title>
            <description>Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally once daily (OD) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the NRS for Sleep Disturbance at Week 12</title>
          <description>In the morning subjects were asked the following question to determine the level of sleep disturbance due to itching: On a scale of 0 (no sleep disturbance) to 10 (awake all night), please rate how much your sleep was disturbed by itch last night.</description>
          <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NRS for pruritus (sleep disturbance) at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" spread="2.172"/>
                    <measurement group_id="O2" value="2.74" spread="2.559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in baseline at Week 12 (sleep disturbance)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="2.417"/>
                    <measurement group_id="O2" value="-0.93" spread="2.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total, Daytime and Night Time Duration of Itching at Week 12</title>
        <description>Subjects were asked the following question to determine their duration of itching: Over the last 12 hours approximately how many hours, if any, did you itch?</description>
        <time_frame>From baseline to week 12</time_frame>
        <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>ZPL-389</title>
            <description>Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally once daily (OD) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total, Daytime and Night Time Duration of Itching at Week 12</title>
          <description>Subjects were asked the following question to determine their duration of itching: Over the last 12 hours approximately how many hours, if any, did you itch?</description>
          <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total duration of itching- Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.74" spread="4.608"/>
                    <measurement group_id="O2" value="6.68" spread="5.637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total duration of itching- Change at week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="4.525"/>
                    <measurement group_id="O2" value="-1.16" spread="5.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daytime duration of itching-Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="2.682"/>
                    <measurement group_id="O2" value="3.57" spread="2.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daytime duration of itching-Change at week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="2.399"/>
                    <measurement group_id="O2" value="3.63" spread="3.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Night time duration of itching-Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" spread="2.072"/>
                    <measurement group_id="O2" value="3.11" spread="2.720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Night time duration of itching-Change at week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="2.188"/>
                    <measurement group_id="O2" value="-0.43" spread="2.581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants for Each Verbal Rating Scale (VRS) Score for Pruritus at Week 12</title>
        <description>Subjects were asked to rate their itch over the last 12 hours using a list of adjectives describing different levels of symptom intensity: Over the last 12 hours how would you rate your itch? No itch; Mild; Moderate and Severe; Pruritus was evaluated by the subject, using the eDiary, twice daily for 1 week prior to the start of study treatment (run-in period) and during treatment (baseline to Day 84).</description>
        <time_frame>From baseline to week 12</time_frame>
        <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>ZPL-389</title>
            <description>Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally once daily (OD) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants for Each Verbal Rating Scale (VRS) Score for Pruritus at Week 12</title>
          <description>Subjects were asked to rate their itch over the last 12 hours using a list of adjectives describing different levels of symptom intensity: Over the last 12 hours how would you rate your itch? No itch; Mild; Moderate and Severe; Pruritus was evaluated by the subject, using the eDiary, twice daily for 1 week prior to the start of study treatment (run-in period) and during treatment (baseline to Day 84).</description>
          <population>FAS: All randomized subjects who received at least one dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - No itch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - No itch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from first dose of study treatment until end of study treatment plus 28 days post treatment up to maximum duration of 16 weeks</time_frame>
      <desc>Adverse events (AEs) are any untoward sign or symptom that occured during the study treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>ZPL-389</title>
          <description>Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally OD for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythrodermic psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of the agreements with investigators may vary. However, the investigator is not prohibited from publishing. Any publications from a single site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

